Fingolimod in Schizophrenia Patients

Summary

This will be a single site safety and proof of concept study conducted at the Indiana University Psychotic Disorders Program. Forty subjects with schizophrenia or schizoaffective disorders will be randomized 1:1 to double-blind treatment with fingolimod or matched placebo for duration of 8 weeks.

Timeline

Start

2013-01

Primary completion

2016-08

Completion

2016-08

Drugs

Indications